TY - JOUR
T1 - Targeted therapies for advanced Ewing sarcoma family of tumors
AU - Jiang, Yunyun
AU - Ludwig, Joseph
AU - Janku, Filip
N1 - Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2015/5
Y1 - 2015/5
N2 - The prognosis of adolescent and young adult patients battling metastatic Ewing sarcoma family of tumors (ESFT) remains less than 30% despite the development of systemic therapies. In the era of personalized medicine, novel molecular targets have been tested in preclinical or clinical settings in ESFT. In this review, we focus on early clinical and translational research that identified multiple molecular targets, including IGF-1R; mTOR; tyrosine kinase inhibitors; EWS-FLI1-related targets, and others. Overall, novel targeted therapies demonstrated modest efficacy; however pronounced and durable antineoplastic responses have been observed in small subsets of treated patients, for example with IGF-1R antibodies. Identifying outcome-predicting biomarkers and overcoming treatment resistance remain major challenges. Due to the rarity of ESFT, multi-institutional collaboration efforts of clinicians, basic and translational scientists are needed in order to understand biology of therapeutic response or resistance, which can lead to development of novel therapeutic methods and improved patient outcomes.
AB - The prognosis of adolescent and young adult patients battling metastatic Ewing sarcoma family of tumors (ESFT) remains less than 30% despite the development of systemic therapies. In the era of personalized medicine, novel molecular targets have been tested in preclinical or clinical settings in ESFT. In this review, we focus on early clinical and translational research that identified multiple molecular targets, including IGF-1R; mTOR; tyrosine kinase inhibitors; EWS-FLI1-related targets, and others. Overall, novel targeted therapies demonstrated modest efficacy; however pronounced and durable antineoplastic responses have been observed in small subsets of treated patients, for example with IGF-1R antibodies. Identifying outcome-predicting biomarkers and overcoming treatment resistance remain major challenges. Due to the rarity of ESFT, multi-institutional collaboration efforts of clinicians, basic and translational scientists are needed in order to understand biology of therapeutic response or resistance, which can lead to development of novel therapeutic methods and improved patient outcomes.
KW - Ewing sarcoma
KW - Targeted therapies
UR - http://www.scopus.com/inward/record.url?scp=84947487028&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947487028&partnerID=8YFLogxK
U2 - 10.1016/j.ctrv.2015.03.008
DO - 10.1016/j.ctrv.2015.03.008
M3 - Review article
C2 - 25869102
AN - SCOPUS:84947487028
SN - 0305-7372
VL - 41
SP - 391
EP - 400
JO - Cancer treatment reviews
JF - Cancer treatment reviews
IS - 5
ER -